Are you Dr. Lee?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 59 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
4499 Medical Dr
Ste 102
San Antonio, TX 78229Phone+1 210-614-0402Fax+1 210-614-2838
Summary
- Dr. Mark Lee, MD is a board certified dermatologist in San Antonio, Texas. He is currently licensed to practice medicine in Texas, Arizona, and California. He is affiliated with Methodist Hospital.
Education & Training
San Antonio Uniformed Services Health Education ConsortiumResidency, Dermatology, 1991 - 1994
Valleywise HealthInternship, Transitional Year, 1987 - 1988
George Washington University School of Medicine and Health SciencesClass of 1987
Certifications & Licensure
AZ State Medical License 1996 - Present
CA State Medical License 1990 - Present
TX State Medical License 1995 - 2025- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) Start of enrollment: 2014 Jun 16
- A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris Start of enrollment: 2015 Apr 01
- A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26) Start of enrollment: 2015 Nov 16
- Join now to see all
Publications & Presentations
PubMed
- 19 citationsTapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics.John E. Jett, Michael McLaughlin, Mark S. Lee, Lawrence Charles Parish, Janet DuBois
American Journal of Clinical Dermatology. 2021-10-28 - 19 citationsA Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis.Robert Bissonnette, Robert S Call, Tooraj Raoof, Zhaoyin Zhu, Swamy Yeleswaram
American Journal of Clinical Dermatology. 2022-05-01 - 10 citationsOral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study.Pablo A Jimenez, Howard L Sofen, Robert Bissonnette, Mark Lee, Joseph Fowler
Journal of the American Academy of Dermatology. 2023-08-01
Professional Memberships
- Fellow
